Literature DB >> 25274859

Recanalization of infrainguinal chronic total occlusions with the crosser system: results of the PATRIOT trial.

John Laird1, James Joye, Naveen Sachdev, Paul Huang, Ronald Caputo, Imran Mohiuddin, John Runyon, Tony Das.   

Abstract

PURPOSE: To evaluate the angiographic and functional outcomes of the Crosser chronic total occlusion (CTO) recanalization system used to facilitate crossing of infrainguinal occlusions resistant to conventional guidewire techniques.
METHODS: Eighty-five patients with a previous or concurrent failed attempt to cross a CTO using conventional guidewire techniques were enrolled at eight United States centers. Occlusions were at least 30 days old and ≤30 cm in length. Primary endpoints included advancement of the recanalization system into or through the occlusion gaining guidewire access in the distal vessel beyond the lesion, and 30-day freedom from clinical perforation requiring treatment.
RESULTS: The average age of occlusion was 16 months, the mean occlusion length was 117.5 ± 84.0 mm, 55.7% had unfavorable morphology for crossing, and 75% were moderately to severely calcified. Superficial femoral artery (SFA) occlusions were most commonly treated (61.2%), followed by popliteal artery (20%), and tibioperoneal (16.5%) occlusions. The CTO was crossed and the guidewire successfully advanced into the distal true lumen in 83.5% of cases. Following adjunctive therapy, 81.2% achieved a satisfactory angiographic result (≤50% residual stenosis). At 30 days post procedure, 98.8% of patients were free from clinical perforation.
CONCLUSION: Use of the Crosser CTO recanalization system facilitated crossing of guidewire-resistant, chronic, infrainguinal occlusions with minimal risk of clinically significant vessel perforation.

Entities:  

Mesh:

Year:  2014        PMID: 25274859

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  8 in total

1.  Endovascular Devices and Revascularization Techniques for Limb-Threatening Ischemia in Individuals With Diabetes.

Authors:  Jayer Chung
Journal:  J Diabetes Sci Technol       Date:  2017-03-28

2.  Percutaneous intentional intra-luminal-assisted recanalization (PILAR technique) of challenging chronic total occlusions using a high-frequency vibration device.

Authors:  Stephanie Volpi; Amine Chouiter; Francois Saucy; Steven Hajdu; Anne-Marie Jouannic; Salah D Qanadli
Journal:  Eur Radiol       Date:  2018-05-22       Impact factor: 5.315

3.  Success rate of endovascular recanalization for femoropopliteal artery total occlusion using the wingman catheter system.

Authors:  Tomofumi Tsukizawa; Masahiko Fujihara; Yuko Yazu; Tasuku Kozasa; Yuma Tanabe
Journal:  Heart Vessels       Date:  2022-09-22       Impact factor: 1.814

Review 4.  Atherectomy vs Other Modalities for Treatment During Peripheral Vascular Intervention.

Authors:  Mohsin Chowdhury; Eric A Secemsky
Journal:  Curr Cardiol Rep       Date:  2022-05-10       Impact factor: 3.955

5.  Recanalization of a Heavily Calcified Chronic Total Occlusion in a Femoropopliteal Artery Using a Wingman Crossing Catheter.

Authors:  Kazunori Horie; Naoto Inoue; Akiko Tanaka
Journal:  Ann Vasc Dis       Date:  2016-06-02

6.  Clinical outcomes after balloon angioplasty with Crosser device for heavily calcified common femoral and popliteal artery disease.

Authors:  Ahmed Elsayed Hassan; Masashi Nakao; Haruka Katsumata; Yusuke Inagaki; Kazuki Tanaka; Hisao Otsuki; Hiroyuki Arashi; Junichi Yamaguchi; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2021-02-26       Impact factor: 2.037

7.  Alternative crossing technique for iliaco-femoro-popliteal CTOs with a catheter only.

Authors:  Marc Cunier; Arash Najafi; Gabriel T Sheikh; Christoph A Binkert
Journal:  CVIR Endovasc       Date:  2019-07-18

8.  Performance of the Wingman catheter in peripheral artery chronic total occlusions: Short-term results from the international Wing-It trial.

Authors:  John R Laird; S Jay Mathews; Marianne Brodmann; Peter A Soukas; Andrej Schmidt
Journal:  Catheter Cardiovasc Interv       Date:  2020-11-19       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.